Bispecific antibody platform technology and its application for cancer therapy

다국어 초록 (Multilingual Abstract)

Bispecific monoclonal antibodies (BsMabs) are one of next generation antibody therapeutics, artificial proteins with architectural modifications that can bind to two different antigens simultaneously. BsMabs have been developed in tremendous number of structural formats. There are additionally required considerations for the development of BsMabs therapeutics unlike monoclonal antibody therapeutics. The structurally modified antibody architecture of BsMabs may induce immunogenic responses in human bodies. The structural heterogeneity may also occur for BsMabs with heterodimeric assembly such as Triomab, Crossmab, orth-Fab IgG, klh IgG. BsMabs have been applied to the areas of cancer immunotherapy. Currently two BsMabs have been approved by FDA and EMA. These BsMabs and their platform technologies will be overviewed in the presentation.